Enlivex Therapeutics Ltd. announced that its primary treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange, effective January 21 2026. The listing expands the number of venues where the token can be traded, giving investors a broader set of options for buying and selling the asset.
WhiteBIT is the largest European exchange by traffic and is part of the W Group, which serves more than 35 million customers worldwide. By adding WhiteBIT to its trading list, Enlivex gains access to a high‑volume market that can improve price discovery and reduce the bid‑ask spread for RAIN, thereby lowering the cost of capital for the company’s treasury operations.
Enlivex’s dual‑strategy model places the RAIN token at the center of its digital‑asset treasury while the company continues to develop Allocetra, a macrophage‑reprogramming therapy for osteoarthritis. The token serves as both a governance and utility token for a decentralized predictions and options protocol on the Arbitrum network. A more liquid token market supports Enlivex’s goal of using digital assets to fund clinical research and potentially strengthen its balance sheet, especially as the company reports no revenue and operates at a loss with an EPS of –$0.55.
The listing is expected to reduce volatility in RAIN’s price, improve liquidity, and provide a new source of capital that can be deployed toward clinical milestones. However, the company remains exposed to regulatory uncertainty surrounding crypto assets and the inherent price swings of digital tokens. Enlivex’s management has acknowledged these headwinds while emphasizing the strategic importance of a robust treasury framework for sustaining its osteoarthritis program.
The announcement was well received by investors, reflecting confidence in Enlivex’s treasury strategy and its continued focus on advancing Allocetra. The company’s decision to delist from the Tel Aviv Stock Exchange and concentrate trading on Nasdaq further signals a strategic shift toward U.S. capital markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.